{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"36.3","value":"14.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Response for CLL/SLL measured using Modified International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 (IWCLL) guidelines. Response for hairy cell leukemia was measured using Consensus resolution: proposed criteria published in Leukemia 1987.","dispersionType":"95% Confidence Interval","groups":[{"description":"The Outcome Measure was assessed in aggregate, combining participants from both phases of the study, as per the planned protocol.\n\nPhase 1, Dose 1 received entospletinib at Dose Level 1: 400 mg daily (200 mg twice daily) in combination with obinutuzumab during Dose Escalation phase of study.\n\nPhase 1, Dose 2 received entospletinib at Dose Level 2: 800 mg daily (400 mg twice daily) in combination with obinutuzumab during Dose Escalation phase of study.\n\nPhase 2, MTD: Received entospletinib at Maximum Tolerated Dose (MTD) in combination with obinutuzumab during Dose Expansion phase of study. The MTD was determined to be 800 mg daily (400 mg twice daily).","id":"OG000","title":"All Research Participants"}],"paramType":"NUMBER","populationDescription":"Efficacy evaluable population: participants with CLL (Phase I/Phase II)","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"Complete Response (CR) Defined as the Percentage of Subjects Who Achieve CR","type":"PRIMARY","unitOfMeasure":"percentage of participants"}